Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold
Source: SeekingAlpha
2025-11-30 01:29:00 ET
Astria Therapeutics: upgrading target price at $13, maintaining hold due to limited upside
Read the full article on Seeking Alpha
For further details see:
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold
Pharvaris N.V.
NASDAQ: PHVS
PHVS Trading
-0.36% G/L:
$26.265 Last:
76,126 Volume:
$26.51 Open:
PHVS Latest News
March 11, 2026 06:50:00 am
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
PHVS Stock Data
$1,492,567,159
37,790,994
N/A
37
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
